Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

BACKGROUND: Atypical teratoid/thabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a 5-year overall survival rate of 15%–45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. Th...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neurooncol Adv
Egile Nagusiak: Morin, Andrew, Soane, Caroline, Pierce, Angela, Sanford, Bridget, Jones, Kenneth L, Crespo, Michele, Zahedi, Shadi, Vibhakar, Rajeev, Mulcahy Levy, Jean M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Basic and Translational Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236404/
https://ncbi.nlm.nih.gov/pubmed/32642704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa051
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak